Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.

The group abandons plans in lung cancer with Met exon 14 skipping, to focus on Met amplifications.

Earnings season begins again, while big readouts loom for ALX and Fibrogen.

Starglo reveals a surprisingly strong survival benefit in an EHA late-breaker.

As BAY2927088 enters phase 3 its lung cancer use will no longer be limited to exon 20.

The group is keeping faith with the novel target KLK2.

Tagrisso is a knockout on PFS, but only OS will show whether it should be given before patients progress.

Paloma-3 data suggest subcutaneous Rybrevant might have an edge over the intravenous formulation.